drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody immunotherapy)
drug_description
Fully human IgG1 anti-CD20 monoclonal antibody immunotherapy administered subcutaneously; depletes CD20+ B lymphocytes via CDC, ADCC, and apoptosis, reducing naive and memory B cells while sparing stem cells and plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Ofatumumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Fully human IgG1 anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes them via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis, reducing naive and memory B cells while sparing hematopoietic stem cells and plasma cells.
drug_name
Ofatumumab (Kesimpta)
nct_id_drug_ref
NCT05634967